Price
No data yet.
Social Signal Score
Revenue
$20.9KCompany Profile
- CEO
- David H. Weinstein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 0.32
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -116.98
Financials
LNAI has only 10 quarterly periods on file — the charts below show the full history available.
Revenue
$20.9K+0.0%Net Income
$-2.57MEBITDA
$-2.45MFree Cash Flow
$-1.03MEPS (diluted)
$-0.80Shares Outstanding (diluted)
3.12M+279.5%Operating Expenses
$1.44MCash & Debt
$3.16MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $0.00 | $-178.01M | $-86.24 |
| 2023 | $0.00 | $-88.43M | $-72.80 |
| 2022 | $0.00 | $-39.68M | $-56.80 |
| 2021 | $0.00 | $-113.43M | $-172.80 |
| 2020 | $0.00 | $-26.72M | $-45.36 |
Valuation
LNAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+33.33%Social Signal Score
Mentions (2)
- Newsprnewswire.com·5h ago·Neutral
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.
View source ↗ - Newsprnewswire.com·8d ago·Negative
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.
View source ↗
Earnings
Mon, Sep 28(in 3 weeks)
Estimates and results for LNAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.